Figure 2.
Individual trajectories of the nine participants on tenofovir, lamivudine and dolutegravir with a viral load result at week 48, who were suppressed at week 24 but not suppressed at week 48
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.